IPO
IPO
Best Performers
Forthcoming Issues
Closed Issues
New Listings
Current Issues
IPO Performance
IPO News
IPO Analysis
Basis of Allotment
Draft Prospectus
  HOME  >  IPO  >   IPO SNAPSHOT
IPO Snapshot    
Emcure Pharmaceuticals Ltd.
Issue Open Date 03-Jul-24  
Issue Closing Date 05-Jul-24  
Application Money 100  
Allotment Money  
Price Band 960 - 1008  
Minimium Application No. 14  
Issue Size (Shares) 13703538  
Market Lot 1.00  
Objective
1. Repayment and/ or prepayment of all or a portion of certain outstanding borrowings availed by our Company; and2. General corporate purposes.
Category No. of Shares No. of Shares Subscription Ratio
  Offered / Reserved Bid For  
Non-Institutional Investors   2949523   142526748   48.32  
Qualified Institutional Buyers   3762896   736891932   195.83  
Retail Individual Investors   6882219   49618982   7.21  
Business Description
We are one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. We were ranked as (i) the 12th largest pharmaceutical company
more...
Promoter's Holding
Total Share Capital   150730468  
Offered to Public   19375070  
Promoter's Holding (Pre-Issue)   83.21  
Promoter's Holding (Post-Issue)   78.11  
Address
Plot No. P-1 & P-2
I T - B T Park
Phase- I I
M I D C
Hinjawadi
Pune ,
Maharashtra ,
411057
Phone: 020-3507003 / 35070000
Email: investors@emcure.com
Website: www.emcure.com
Registrar
Link Intime India Pvt Ltd.
C 101
247 Park
LBS Marg
Vikhroli (West)
Mumbai
Listed at
BSE, NSE
Lead Manager
Axis Capital Ltd.
Jefferies India Pvt Ltd.
JP Morgan India Pvt Ltd
Kotak Mahindra Capital Co Ltd
Promoters
Namita Vikas Thapar
Samit Satish Mehta
Satish Ramanlal Mehta
Sunil Rajanikant Mehta
Back Back TopTop
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA
Publishing of investor charter information | Annexure A – Investor charter of brokers |
Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.